[go: up one dir, main page]

AR036079A1 - Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados - Google Patents

Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados

Info

Publication number
AR036079A1
AR036079A1 ARP020102075A ARP020102075A AR036079A1 AR 036079 A1 AR036079 A1 AR 036079A1 AR P020102075 A ARP020102075 A AR P020102075A AR P020102075 A ARP020102075 A AR P020102075A AR 036079 A1 AR036079 A1 AR 036079A1
Authority
AR
Argentina
Prior art keywords
hydrogen
alkyl
compounds
halo
phenyl
Prior art date
Application number
ARP020102075A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR036079A1 publication Critical patent/AR036079A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • C07D213/34Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Se describen y reivindican compuestos de N-[benzoil]-fenilsulfonamidas de fórmula (1) donde X es O o NH; R1 es hidrógeno, halo, alquilo C1-6, alcoxi C1-4, alquiltio C1-4, CF3, OCF3, SCF3, (alcoxi C1-4)carbonilo, nitro, azido, O(SO2)CH3, N(CH3)2, hidroxi, fenilo, fenilo sustituido, piridinilo, tienilo, furilo, quinolinilo, o triazolilo; R2 es hidrógeno, halo, ciano, CF3, alquilo C1-6 (alcoxi C1-4)carbonilo, alcoxi C1-4, fenilo o quinolinilo; R2a es hidrógeno o alcoxi C1-4; R2b es hidrógeno, halo, alquilo C1-6, con la condición de que al menos uno de R2a y R2b sea hidrógeno; R3 es hidrógeno, halo, alquilo C1-6, CF3 o nitro; R3a es hidrógeno, halo o alquilo C1-6, con la condición de que cuando R3a es alquilo C1-6, R3 sea hidrógeno y R4 sea halo, y R4 es halo, alquilo C1-6 o CF3, con la condición de que solo uno de R3 y R4 puede ser alquilo C1-6 y con la condición de que cuando R4 es halo o alquilo C1-6, sólo uno de R3 y R3a sea hidrógeno; o una sal de adición de base farmacéuticamente aceptable del mismo, con la condición de que: a) cuando tanto R3 como R4 son cloro y R2 es hidrógeno, R1 sea bromo, yodo, alcoxi C1-4, alquiltio C1-4, CF3, OCF3, nitro, azido, O(SO2)CH3, N(CH3)2, hidroxi, fenilo, fenilo sustituido, piridinilo, tienilo, furilo o triazolilo y b) cuanto tanto R3 como R4 son cloro y R1 es hidrógeno, R2 sea bromo, fluoro, CF3, alquilo C1-6, alcoxi C1-4, fenilo o quinolinilo. Dichos compuestos son de aplicación en la manufactura de composiciones farmacéuticas-medicamentos- adaptadas para el tratamiento de neoplasmas susceptibles, mediante la administración de cantidades efectivas de los compuestos mencionados. Se describen y reivindican además, los objetos restantes mencionados en el título.
ARP020102075A 2001-06-06 2002-06-04 Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados AR036079A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06

Publications (1)

Publication Number Publication Date
AR036079A1 true AR036079A1 (es) 2004-08-11

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102075A AR036079A1 (es) 2001-06-06 2002-06-04 Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados

Country Status (35)

Country Link
US (1) US7183320B2 (es)
EP (1) EP1401806B1 (es)
JP (1) JP4167173B2 (es)
KR (1) KR100880760B1 (es)
CN (1) CN100475787C (es)
AR (1) AR036079A1 (es)
AT (1) ATE335722T1 (es)
AU (1) AU2002259204B2 (es)
BR (1) BR0210078A (es)
CA (1) CA2446719A1 (es)
CR (1) CR7182A (es)
CY (1) CY1105386T1 (es)
CZ (1) CZ20033296A3 (es)
DE (1) DE60213810T2 (es)
DK (1) DK1401806T3 (es)
EA (1) EA005810B1 (es)
EC (1) ECSP034874A (es)
EG (1) EG24356A (es)
ES (1) ES2269688T3 (es)
HR (1) HRP20031000A2 (es)
HU (1) HUP0400114A3 (es)
IL (1) IL158985A0 (es)
MX (1) MXPA03011197A (es)
MY (1) MY136855A (es)
NO (1) NO20035366L (es)
NZ (1) NZ529098A (es)
PE (1) PE20030199A1 (es)
PL (1) PL367188A1 (es)
PT (1) PT1401806E (es)
SK (1) SK14642003A3 (es)
SV (1) SV2003001076A (es)
TW (1) TWI266761B (es)
UA (1) UA74889C2 (es)
WO (1) WO2002098848A1 (es)
ZA (1) ZA200308644B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290592A1 (en) 2002-11-22 2004-06-18 Eli Lilly And Company Antitumor benzoylsulfonamides
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005117543A2 (en) * 2004-05-26 2005-12-15 Abbott Laboratories N-sulfonylcarboximidamide apoptosis promoters
WO2006030947A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
DE602006021401D1 (de) * 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
CA2599301A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel use of sulfonamide compound in combination with angiogenesis inhibitor
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
EP2015070A4 (en) 2006-04-20 2010-04-21 Eisai R&D Man Co Ltd Novel marker for sensitivity against sulfonamide compound
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101675033A (zh) 2007-05-16 2010-03-17 霍夫曼-拉罗奇有限公司 芳基吡啶基磺酰胺衍生物,它们的制备和作为药剂的应用
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN106045893A (zh) * 2009-01-19 2016-10-26 Abbvie 公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
KR200457823Y1 (ko) * 2009-05-08 2012-01-05 황정용 쭈꾸미 포획용 어구
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101920202B1 (ko) 2009-05-26 2018-11-21 애브비 아일랜드 언리미티드 컴퍼니 암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2550258B1 (en) * 2010-03-25 2015-08-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
IL225340A (en) 2010-10-29 2017-05-29 Abbvie Inc Solid dispersions containing cell mortality
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SI2643322T1 (en) 2010-11-23 2018-01-31 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US20120129853A1 (en) 2010-11-23 2012-05-24 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (zh) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 一种取代的磺酰胺基(硫代)羰基化合物及其用途
MA41542A (fr) 2015-02-13 2021-04-14 Oxford Drug Design Ltd Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
CN105753748B (zh) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 一种医药中间体磺酰类化合物的合成方法
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
CN116589459B (zh) 2017-04-18 2026-01-30 重庆复创医药研究有限公司 凋亡诱导剂
WO2018237163A1 (en) * 2017-06-23 2018-12-27 Roman Manetsch 5-aminolevulinate synthase inhibitors and methods of use thereof
KR20200094215A (ko) * 2017-12-29 2020-08-06 공윈 바이오팜 컴퍼니, 리미티드 (타이완) 벤젠술폰아미드 유도체 및 지질 래프트 조정 방법
CN114790149B (zh) * 2021-01-26 2024-11-19 江苏中旗科技股份有限公司 一种以2-氯-4-氟苯胺为原料合成2-氯-4-氟苯甲酸的方法
WO2025031360A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
JP2679498B2 (ja) * 1991-12-25 1997-11-19 王子製紙株式会社 感熱記録体
CA2110524A1 (en) 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
US5728712A (en) 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
DE69628050T2 (de) 1995-10-25 2004-04-01 Senju Pharmaceutical Co., Ltd. Angiogenese Hemmer
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6380167B1 (en) * 1999-02-12 2002-04-30 Primecyte, Inc. Methods for anti-tumor therapy
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters

Also Published As

Publication number Publication date
JP4167173B2 (ja) 2008-10-15
ATE335722T1 (de) 2006-09-15
PE20030199A1 (es) 2003-03-12
ECSP034874A (es) 2004-01-28
KR100880760B1 (ko) 2009-02-02
SV2003001076A (es) 2003-07-29
DK1401806T3 (da) 2006-11-27
PL367188A1 (en) 2005-02-21
HUP0400114A3 (en) 2007-05-02
DE60213810T2 (de) 2007-02-01
HK1064360A1 (en) 2005-01-28
EA200400006A1 (ru) 2004-06-24
ZA200308644B (en) 2005-02-07
ES2269688T3 (es) 2007-04-01
MY136855A (en) 2008-11-28
CA2446719A1 (en) 2002-12-12
EP1401806A1 (en) 2004-03-31
AU2002259204B2 (en) 2008-01-17
WO2002098848A1 (en) 2002-12-12
US20040157741A1 (en) 2004-08-12
CN100475787C (zh) 2009-04-08
KR20040007656A (ko) 2004-01-24
PT1401806E (pt) 2006-11-30
HUP0400114A2 (hu) 2005-04-28
BR0210078A (pt) 2004-06-22
JP2004530709A (ja) 2004-10-07
DE60213810D1 (de) 2006-09-21
EA005810B1 (ru) 2005-06-30
SK14642003A3 (sk) 2004-12-01
IL158985A0 (en) 2004-05-12
MXPA03011197A (es) 2004-02-26
CY1105386T1 (el) 2010-04-28
CN1514824A (zh) 2004-07-21
US7183320B2 (en) 2007-02-27
UA74889C2 (en) 2006-02-15
CZ20033296A3 (cs) 2004-04-14
NO20035366L (no) 2004-02-06
NZ529098A (en) 2005-08-26
CR7182A (es) 2004-06-08
HRP20031000A2 (en) 2004-04-30
TWI266761B (en) 2006-11-21
NO20035366D0 (no) 2003-12-02
EP1401806B1 (en) 2006-08-09
EG24356A (en) 2009-03-04

Similar Documents

Publication Publication Date Title
AR036079A1 (es) Compuestos de [n-benzoil]-fenilsulfonamida y de n-[fenilsulfonil]-benzamidina;metodos para tratar neoplasias en mamiferos susceptibles, utilizando dichos compuestos y composiciones formuladas con dichos compuestos aplicables en los metodos mencionados
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
SE0300956D0 (sv) Stabilisatorblandningar
BRPI0014869B8 (pt) prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
DK1485359T3 (da) Natriumkanalblokkere
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
DE60114994D1 (de) Blutplättchen-adp-rezeptor-inhibitoren
AR004002A1 (es) Composicion util especialmente para el tratamiento y la proteccion de los animales domesticos infestados o susceptibles de ser infestados por parasitos
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
KR880007460A (ko) 3-헤테로-치환된-n-벤질-인돌
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
PE20040907A1 (es) Derivados de anilinopirazol
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
PL353646A1 (en) Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
PL352944A1 (en) Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
CO5080727A1 (es) Ligandos azabiciclicos de receptores 5 ht1
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht
AR058720A1 (es) Derivados 2-feniletilamino y composicion farmaceutica
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
PL341539A1 (en) Heterocyclic toxins of topoisomerases
CO6180505A2 (es) Metodos para el tratamiento de transtornos cocleares y vestibulares

Legal Events

Date Code Title Description
FB Suspension of granting procedure